Objective. Recent studies have identified a number of novel rheumatoid arthritis (RA) susceptibility loci in Caucasian populations. The aim of this study was to determine whether the genetic variants at 4q27, 6q23, CCL21, TRAF1/C5, and CD40 identified in Caucasians are also associated with RA in a Korean case-control collection. We also comprehensively evaluated the genetic variation within PTPN22, a well-established autoimmune disease-associated gene.
in Caucasian patients with RA contributed significantly to disease in Koreans. Although tag SNPs covering the PTPN22 linkage disequilibrium block were polymorphic, they did not reveal any disease association, and resequencing did not identify any new common coding region variants in this population. The 6q23 and 4q27 SNPs assayed were nonpolymorphic in this population, and the TRAF1/C5, CD40, and CCL21 SNPs did not show any evidence for association with RA in this population of Korean patients.
Conclusion. The genetic risk factors for RA are different in Caucasian and Korean patients. Although patients of different ethnic groups share the HLA region as a major genetic risk locus, most other genes shown to be significantly associated with disease in Caucasians appear not to play a role in Korean patients with RA.
Rheumatoid arthritis (RA) is a chronic autoimmune arthritis characterized by progressive joint destruction. Both genetic and environmental factors have been shown to play a role in the development of RA. Although the largest genetic risk factor predisposing to RA, a common set of alleles at HLA-DRB1, has been associated with RA in populations of both Caucasian and Asian ancestry (1, 2) , many other risk loci have been shown to confer RA susceptibility in only 1 ethnic group. For example, although PTPN22 has been consistently shown to be associated with RA in Caucasians, the 620W risk allele in this gene is not found and thus is not disease-associated in Asian populations (3) (4) (5) (6) (7) . In contrast, PADI4, SLC22A4, and FCRL3 have been associated with RA in studies of Asian patients, but the associations were weak or negative in populations of European ancestry (6, (8) (9) (10) (11) (12) (13) (14) . Although these results suggest that the genetic risk alleles that confer susceptibility to RA are heterogeneous across major ethnic groups, recent reports have identified a common STAT4 haplo-type that confers a similar degree of risk of RA in both Asian and Caucasian populations (15, 16) .
Outside of the HLA region, the R620W variant of the PTPN22 gene is the most consistently and most strongly disease-associated variant identified in RA association studies performed in Caucasian populations. Although this variant is not found in Asians, it is possible that other variants within this important candidate gene could contribute to genetic susceptibility to RA in Asian populations. In addition to PTPN22, new RA susceptibility loci in Caucasian populations have been identified in several recent genetic studies. The TRAF1/C5 locus has been identified both by a genome-wide association study and as a candidate gene (7, 17) . Two independent followup genome-wide association studies identified a susceptibility locus on 6q23 near TNFAIP3 (18, 19) . A large meta-analysis using genome-wide association and replication collections identified the CD40 and CCL21 loci (20) , and a 4q27 region including IL2/IL21 has been identified through a candidate gene approach after being shown to be associated with other autoimmune diseases (21) . To date, there has been no study in an Asian population of SNPs in these new regions associated with RA. Therefore, the aim of this study was to determine whether PTPN22 variants or any of 5 diseaseassociated SNPs recently identified in Caucasians also contribute to RA in Koreans.
PATIENTS AND METHODS
Study population. The study group comprised 1,128 Korean patients with RA who were enrolled consecutively from the outpatient clinic of the Hospital for Rheumatic Diseases, Hanyang University, Seoul, South Korea and 1,022 ethnically matched control subjects for whom no history of RA or other autoimmune diseases was noted in the self-reported questionnaire at the time of enrollment. All patients with RA met the American College of Rheumatology (formerly, the American Rheumatism Association) 1987 revised criteria for the classification of RA (22) . The study was approved by the institutional review board of Hanyang University Hospital. Written informed consent was obtained from all participants.
All subjects were typed for HLA-DRB1 subtypes, using polymerase chain reaction (PCR) and sequence-specific oligonucleotide probe hybridization. Because the second most significant risk allele for RA in the Korean population was DRB1*0901, we regarded DRB1*0901 as a member of the shared epitope (SE) group, in addition to the following alleles: DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0413, *1001, and *1402. Among 1,128 patients with RA, cyclic citrullinated peptide (CCP) antibody data were available for 807 patients. These data were based on quantitative duplicate measurements by enzyme-linked immunosorbent assay, using the DI-ASTAT anti-CCP kit (FCCP 200; Axis-Shield, Dundee, Scotland, UK) according to the manufacturer's instructions. The staging system proposed by Steinbrocker et al (23) was used as a measure of the radiographic severity of RA.
PTPN22 resequencing. Genomic DNAs from 48 rheumatoid factor-positive Korean patients with RA were sequenced over the regions representing the promoter region (up to Ϫ2,000 bp), all 21 exons including exon-intron boundaries, and the 3Ј-untranslated region of PTPN22, using standard dideoxy DNA sequencing techniques (Polymorphic DNA Technologies, Alameda, CA).
SNP selection and assay design. We used the Tagger method (ref. 24 , and http://www.broad.mit.edu/mpg/tagger/) to select SNPs polymorphic in the HapMap combined Han Chinese in Beijing (CHB) and Japanese in Tokyo (JPT) database (25) across the 400-kb linkage disequilibrium block that includes PTPN22. In addition, all variants identified from the PTPN22 exon resequencing were selected. A total of 34 SNPs/variants were selected from the PTPN22 linkage disequilibrium block. Last, we identified SNPs that have been reported as associated with RA in either a Caucasian (TRAF1/C5, 6q23, 4q27, CD40, and CCL21 loci) or Asian (PADI4) population and selected 1 disease-associated SNP per region (a total of 6 SNPs were selected). The 40 selected SNPs were used to design multiplex genotyping assays using Sequenom RealSNP (www.realsnp.com) and eXTEND applications (Sequenom, San Diego, CA).
Genotyping. Multiplex PCR was used to amplify DNA products containing up to 25 SNPs in a single reaction from 5 ng genomic DNA. Synthetic oligonucleotides that bind adjacent to the SNP site were then hybridized and extended with nucleotides complementary to the template SNP site, using modified nucleotides that terminate the extension reaction at the interrogated SNP and generate alternate products of mass sufficiently different to be separated by mass spectrometry. The extended products were separated by matrixassisted laser desorption ionizationϪtime-of-flight mass spectrometry, and the genotypes were determined by SpectroTyper software (Sequenom). Calls were evaluated and edited by cluster analysis, which was performed with SpectroTyper software, version 4.0.
Statistical analysis. Association tests for SNPs and haplotypes in patients and control subjects and the regional linkage disequilibrium structure for analyzed SNPs were determined using Haploview software, version 4.0 (26) . We excluded SNPs with significant deviation from HardyWeinberg equilibrium (P Ͻ 0.005) and SNPs with a minor allele frequency in controls of Ͻ0.01. We reanalyzed the association of all SNPs with specific subgroups of RA (CCP antibody-positive RA, severe erosive RA, or SE-positive RA) using multivariate logistic regression with adjustments for age and sex. These subgroup analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, NC).
RESULTS
Characteristics of the patients and control subjects. Among the patients with RA, the mean Ϯ SD age was 52.4 Ϯ 11.9 years, the mean Ϯ SD age at disease onset was 39.9 Ϯ 11.5 years, 89.7% were female, 81.4% were positive for the SE, 17.0% showed no erosive changes (Steinbrocker stage I), and 83.0% demonstrated erosions (Steinbrocker stages II, III, and IV). Among RA patients with CCP antibody data (n ϭ 807), 681 (84.4%) were anti-CCP positive. The mean Ϯ SD age of control subjects was 36.8 Ϯ 12.5 years, and 86.3% were female.
PTPN22 sequence variants identified by resequencing. Nineteen sequence variants (i.e., variants identified in 1 or more resequenced DNAs) were identified in the exonic (exons and intronic splice junction regions) and the promoter regions of PTPN22 in the resequenced Korean DNA samples. Of these, 13 had previously been identified, and 6 were novel. The novel variants were submitted to the Database of SingleNucleotide Polymorphisms (dbSNP; http://www.ncbi. nlm.nih.gov/SNP/) (the ss numbers are as follows: ss103510562, ss103510564, ss103510567, ss103510570, ss103510573, and ss103510576). Although all of the novel variants were rare (i.e., found in only a single DNA of the 48 resequenced), they were included in the casecontrol genotyping. One of the novel variants was found in the promoter region, 4 were intronic, and 1 was a splice junction variant.
Genotype assay results. Of the 40 SNPs included in the assay design, assays for 2 SNPs failed ( 368 LEE ET AL which had a 77.7% call rate. No patients or control subjects were polymorphic at rs2476601 (R620W), while 1-9 minor alleles (of 4,300 alleles) were present in the 6 novel PTPN22 variants, the 6q23 SNP rs6920220, and the 4q27 SNP rs6822844 (Supplementary Table 1 and  Table 2 ). Additionally, the PTPN22 tag SNP rs1018592 was not analyzed, because of significant deviation from Hardy-Weinberg equilibrium.
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RA association tests.
No statistically significant association (P Ͻ 0.05) with RA was detected between any of the 24 polymorphic PTPN22 tag SNPs (Table 1  and Supplementary Table 1 ) from the linkage disequilibrium block covering the AP4B1, C1orf178, PTPN22, RSBN1, PTHF1, and MAG13 genes. In addition, Caucasian RA-associated SNPs at TRAF1/C5, CD40, and CCL21 were found to be polymorphic in the Korean population but not to be associated with disease ( Table  2 ). As noted above, the 4q27 and 6q23 variants were too rare in this population to be evaluated for association ( Table 2 ). The PADI4 SNP rs2240340 was noted to be strongly disease-associated, with a P value of 1.15 ϫ 10 Ϫ8 and an odds ratio of 1.43 (95% confidence interval 1.26-1.62) for the presence of the disease-associated T allele on patient chromosomes compared with control chromosomes (Table 2 ). In the subgroup analyses, there were no significant genotypic or allelic associations of any of these SNPs in subgroups of patients classified according to radiographic severity (Steinbrocker stage I and stages II-IV), SE status (SE positive and SE negative), and the CCP status (CCP antibody positive and CCP antibody negative) compared with control subjects, except for PADI4 SNP rs2240310, which was significantly associated with RA irrespective of SE status (P Ͻ 0.01) or CCP antibody positivity (P Ͻ 0.0001).
PTPN22 linkage disequilibrium. The linkage disequilibrium structure of the broad genomic region containing the PTPN22 gene was similar in individuals in the HapMap Centre d'Etude du Polymorphisme Humain Utah residents with ancestry from northern and Western Europe (CEU) and the combined CHB and JPT populations, with a 400-kb region of strong linkage disequilibrium containing 6 genes (MAGI3, PHTF1, RSBN1, PTPN22, C1orf178, AP4B1) identified in both populations (see Supplementary Figure 1 , available on the Arthritis & Rheumatism Web site at http://www3. interscience.wiley.com/journal/76509746/home). The 24 PTPN22 tag SNPs that passed quality control captured (r 2 Ͼ 0.8) 90% of the 185 HapMap variants within the 400-kb region that had a minor allele frequency of Ͼ5% in the CHB ϩ JPT population. Although the linkage disequilibrium structure of the PTPN22 gene region was similar in individuals in the HapMap CEU and CHB ϩ JPT populations, the frequencies of the common haplotypes in these 2 populations were very different. Eleven of the 13 tag SNPs used for the haplotype association analysis of the 85-kb PTPN22 gene region (see below) were genotyped in the HapMap CHB ϩ JPT and CEU samples. These 11 SNPs defined only 4 common haplotypes (those with Ͼ5% frequency) in both populations. All 4 common haplotypes found in the Asian samples were also common haplotypes in the CEU samples, but the haplotype frequencies were strikingly different between the 2 populations (Table 3) . Interestingly, the 620W autoimmune disease-associated variant was found only on a portion (approximately half) of the copies of haplotype 1 in the CEU samples, but was not found on any of the haplotype 1 copies in the CHB ϩ JPT samples (Table 3) .
Haplotype analysis. PTPN22 haplotypes were constructed using the SNPs from Table 1 , numbers 6 through 25, including only those with a minor allele frequency Ͼ0.05, using Haploview software. These 13 SNPs covered the entire 85-kb PTPN22 gene region. The 4 common haplotypes (each with a frequency Ͼ5%) together accounted for 96.6% of the chromosomes of the individuals genotyped. Association tests were performed for each of these 4 haplotypes, and none were found to be associated with disease (Table 4) .
DISCUSSION
Recent whole-genome association studies in European ancestry case-control collections have shown that after HLA variants, SNPs within the PTPN22 genetic region are consistently the second most significantly disease-associated variants in the genome (3,7). Table 2 , with the addition of 2 single-nucleotide polymorphisms, rs1217412 and rs3761935. The A allele of rs1217412 was found only on haplotype 1B, and the G allele of rs3761935 was found only on haplotype 2. OR ϭ odds ratio; 95% CI ϭ 95% confidence interval.
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However, the proposed causative variant, an SNP encoding a structural variant (R620W) of the PTPN22 protein, is not present in the Asian population. We therefore sought to determine whether other PTPN22 alleles are associated with RA in Asian patients. We also evaluated variants in 5 other loci that have strong evidence for association in Caucasians with RA in a large Korean RA case-control series. SNP variants within the PTPN22 linkage disequilibrium block were evaluated using a tag SNP approach to interrogate the known common variants in the region. None of the 24 polymorphic SNPs covering the genomic region including PTPN22 were associated with susceptibility to RA in this Korean population. Of note, we have confirmed that the R620W variant is nonpolymorphic in this population and have shown that a promoter SNP, rs2488457, which has been reported to be associated with RA in Caucasians and with type 1 diabetes mellitus in Japanese (27) , had no evidence for association in Korean patients with RA. The genotyped SNPs cover 90% of the known polymorphic SNPs in the 400-kb PTPN22 linkage disequilibrium block (r 2 Ͼ 0.8), and none were associated with disease. Furthermore, none of the 4 common PTPN22 haplotypes were associated with disease. Coupled with the fact that no common PTPN22 structural variants were identified by resequencing, these data provide strong evidence that common PTPN22-region genetic variants are not associated with RA in this population. This is in stark contrast to the very strong association signals seen in multiple case-control studies in Caucasians with RA.
Although none of the common PTPN22 variants were associated with disease, the novel rare variants are more difficult to evaluate. Interestingly, 3 of the novel variants identified (1 promoter and 2 intronic) were found in a single patient with RA but in no control subjects. Further work will be required to determine whether any of the rare variants of PTPN22 might be private mutations that contribute to disease susceptibility.
This study also demonstrated that SNPs in 5 additional regions (TRAF1/C5, 6q23, 4q27, CD40, and CCL21) that are strongly associated with RA in Caucasians are either nonpolymorphic (6q23 and 4q27) or are not associated with RA in Korean patients (TRAF1/C5, CD40, and CCL21). For these SNPs, we can say with certainty only that the SNP associated with disease in Caucasians is not associated with disease in Koreans. Further investigation and fine mapping similar to what we have done with PTPN22 would be needed to determine whether other polymorphic SNPs in these regions are associated with RA in Koreans. In comparison, we genotyped the PADI4 SNP rs2240340, for which we previously reported an association in a subset (545 patients and 392 control subjects) of this case-control series (9) , and found a striking association, with a P value for association of 1.15 ϫ 10 Ϫ8 , in this larger collection.
These data provide convincing evidence that the genetic risk factors for RA differ substantially between Asian and Caucasian populations. Although the HLA region has been clearly demonstrated to be the most substantial genetic risk factor in populations of both ancestries, the other genetic contributions seem to be very different. PTPN22 consistently has the second strongest genetic effect in whole-genome association studies in Caucasians, yet our data indicate that not only is the R620W variant not present in Koreans, but also that no other common polymorphisms in the region are significant risk alleles in Koreans. The other loci associated with RA in Caucasians for which we assayed SNPs (TRAF1/C5, 6q23, 4q27, CD40, CCL21) were derived from rigorously interpreted and well-replicated studies and probably represent many of the next tier of susceptibility loci in populations of European ancestry. The fact that none of these SNPs demonstrated association in this large Korean study reveals a large degree of genetic heterogeneity of RA across continental ancestry differences, especially when juxtaposed with the PADI4 locus, which has been strongly associated with RA in this and other Asian populations but which has shown little evidence for association in Caucasians (14) .
In conclusion, we observed no association between RA in Koreans and tag SNPs covering the entire PTPN22 region or with individual SNPs shown to be strongly associated with disease in Caucasians at the TRAF1/C5, 6q23, 4q27, CD40, and CCL21 loci. When contrasted with other loci such as PADI4, FCRL3, and SLC22A4, which have been shown to be associated with RA in Asian but not Caucasian populations, these data indicate that most of the disease-associated variants have arisen independently in different continental populations, and that different points in disease-associated pathways are influenced by genetic risk factors in the different populations. Therefore, one would expect that whole-genome association studies in Asian populations would reveal more and different susceptibility loci than those that have been described in Caucasian patients with RA. The identification of such loci should expand our understanding of the processes that lead to the development of RA. 370 LEE ET AL
